Status:
COMPLETED
Omitting of Lymphadenectomy is Acceptable for Lung Cancer Smaller Than 6 mm in Solid Size
Lead Sponsor:
Liang Chen
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
Many studies suggested that selective lymph node sampling was acceptable for specific non-small cell lung cancer (NSCLC). This study aimed to evaluate the acceptability of omitting of lymphadenectomy ...
Detailed Description
Many studies suggested that selective lymph node sampling was acceptable for specific non-small cell lung cancer (NSCLC). This study aimed to evaluate the acceptability of omitting of lymphadenectomy ...
Eligibility Criteria
Inclusion
- pathologically confirmed non-small cell lung cancer (NSCLC)
- the maximum tumor diameter ≤2 cm
- receiving surgical treatment between 2009-2022
Exclusion
- non-primary NSCLC;
- with small cell lung cancer components;
- undergoing preoperative neoadjuvant therapies;
- with compromised resection;
- malignant tumor history over the past five years.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
2713 Patients enrolled
Trial Details
Trial ID
NCT06516796
Start Date
January 1 2023
End Date
February 1 2024
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029